BioStock: Medivir optimizes study design after meeting FDA

Medivir has held another meeting with the FDA concerning the upcoming global phase IIb study, in which the company’s drug candidate, fostrox, will be evaluated in combination with Lenvima in liver cancer patients. The aim is to initiate the study in the US by early 2025.
– We have great momentum in the development program with fostrox right now, says Medivir’s CEO Jens Lindberg.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/04/medivir-optimizes-study-design-after-meeting-fda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/